An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over

Sarcopenia Clinical Trial

— SARA-OBS  

Official title:

Characterising SARcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over at Risk of Mobility Disability. An OBServational Clinical Trial (SARA-OBS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03021798
• Other study ID #: BIO101-CL02
• Status: Completed
• Start date: February 8, 2017
• Est. completion date: June 30, 2020

Study information

• Verified date: July 2020
• Source: Biophytis
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The SARA-OBS is a single arm phase 2 clinical trial, with no investigational product and no therapeutic intervention that will be conducted in three European countries, (Belgium, France and Italy), and in the US.

300 community dwelling older adults (men or women≥65 years) reporting loss of physical function and at risk of mobility disability, will undergo mobility functional evaluation and Dual-energy X-ray Absorptiometry DXA scan for body composition determination twice, at six-month interval.

Participants aged ≥ 65 years complaining of poor physical function will be selected to perform SPPB (Short Physical Performance Battery)tests. Those with SPPB scores ≤ 8/12 will be selected to perform body composition analysis with DXA Scan. Participants with ALM/BMI < 0.789 in men and 0.512 in women will be included. The investigational phase will comprise two main visits: the inclusion visit and the 6-month visit. Both the 6-minute walk distance test and the 400-metre walking test will be administered at the main visits. Patient Reported Outcomes (PROs) will be completed by the patients at the same visits.

Description:

The SARA-OBS is a phase 2 clinical trial, with no investigational product and no therapeutic intervention. It will be conducted in three European countries, Belgium, France and Italy, and in the US.

300 community dwelling older adults (men or women≥65 years) reporting loss of physical function and at risk of mobility disability, will undergo mobility functional evaluation and Dual-energy X-ray Absorptiometry DXA scan for body composition determination twice, at six-month interval.

The general objective is to characterise sarcopenia including "sarcopenic obesity" in a population of older persons living in the community and at risk of mobility disability; evaluate their physical performance and body composition in view of the design of a phase 2 clinical study on the efficacy and safety of BIO101 on the prevention of mobility disability in the at-risk community dwelling older adults (≥65 years) reporting loss of physical function.

The primary objective characterise sarcopenia including sarcopenic obesity, in older persons at risk of mobility disability. Sarcopenia will be defined according to the criteria of the Foundation of NIH; the risk of mobility disability will be operationalised by the Short Physical Performance Battery (SPPB). For this purpose, the 6-minute walking distance and the 400-meter walking test will be evaluated at 6-month intervals, in the absence of any therapeutic intervention. The incident rate of change will be estimated on the sample and pre-specified subgroups (e.g. gender, SPPB baseline score, etc.).

Two important Secondary Objectives are also included :

1. To evaluate muscle strength (handgrip/knee extension) and stair power climbing test

2. To evaluate self-administered quality-of-life tests as putative patient reported outcomes (PROs): Short Form Health Survey (SF-36) and Sarcopenia Quality of Life (SarQol) for all subjects; in addition, TSD-OC for participants with BMI≥30

Exploratory objectives are :

1. To measure tentative biomarkers of sarcopenia and poor physical performance, and test their correlation with physical function change over the study observation.

2. To record actimetry via a connected wearable device, in order to describe daily physical activity and possibly identify patterns predictive of improvement/worsening of physical function.

Primary endpoints are the 6-minute Walk Test/400m Walking Test and Co-Primary endpoints are SF-36 and SarQoL for all subjects; additionally TSD-OC for subjects with BMI ≥ 30.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 218
• Est. completion date: June 30, 2020
• Est. primary completion date: November 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 95 Years

Eligibility

Inclusion Criteria:

1. Men and women aged = 65 years and living in the community, reporting loss of physical function

2. Short Physical Performance Battery (SPPB) score = 8

3. ALM/BMI < 0.789 in men and 0.512 in women, by DXA scan

Exclusion Criteria:

1. Unable or unwilling to provide informed consent

2. Unable to understand and perform the functional tests, as judged by the Investigator

3. Current treatment with anabolic drugs, i.e. testosterone

4. Clinical conditions:

1. Current diagnosis major psychiatric disorders.

2. Alcohol abuse or dependence

3. Severe arthritis

4. Cancer requiring active treatment

5. Lung disease requiring regular use of supplemental oxygen

6. Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents

7. Severe cardiovascular disease (including New York Heart Association [NYHA] class III or IV congestive heart failure, clinically significant valvular disease, history of cardiac arrest, presence of an implantable defibrillator, or uncontrolled angina)

8. Parkinson's disease or other progressive neurological disorder

9. Renal disease requiring dialysis

10. Chest pain, severe shortness of breath, or occurrence of other safety concerns during the baseline the 6MWT, or the 400-meter walk test

5. Current physical/rehabilitation therapy

6. Current enrolment in another clinical trial

7. Concomitant condition implying life expectancy = 6 months

8. Any other condition precluding the regular participation to the clinical trial, as judged by the Investigator.

Related Conditions & MeSH terms

• Gait Disorders in Old Age
• Muscle Weakness
• Obesity
• Sarcopenia

Intervention

Other:
• No Drug and no aspecific intervention
No intervention

Locations

Country	Name	City	State
Belgium	Université de Liège	Liège
France	Centre Hospitalier Lyon Sud 165 Chemin du Grand Revoyet	Pierre-Bénite
France	Gérontopole Toulouse	Toulouse
Italy	Sapienza University of Rome	Roma
United States	Jean Mayer USDA Human Nutrition research Center on Aging Tufts University	Boston	Massachusetts
United States	Institut On Aging	Gainesville	Florida
United States	Columbia University New York	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Biophytis

Countries where clinical trial is conducted

United States,  Belgium,  France,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6-minute or 400 meters walk.	The 6 minutes walking distance is a functional exercise capacity test that involves measuring the distance covered by a participant within a specified time of 6 minutes. The 400 meter walking test is a measure of how long it will take for a volunteer to complete the specified 400 meters distance.	Change from Baseline 6 minute or 400 meters to measurement at 6 months.
Secondary	SPPB	Physical performance tests corresponding to standing balance, walking speed and chair stand will be assessed	Change from Baseline SPPB to measurement at 6 months.
Secondary	DEXA	Body composition especially Lean Body Mass and Fat Mass will be measured. This will allow definition of the appendicular Lean Body mass.	Change from Baseline DEXA to measurement at 6 months.
Secondary	Stair Climb Power Test	The ability to ascend and descend stairs (9 stairs of 20 cm height) will be assessed in a specific period of time	Change from Baseline Stair Climb Power Test to measurement at 6 months.
Secondary	Actimetry	The continuous physical activity of the volunteers will be recorded using a specific device during the 6-month study period.	Change from actimetry at Month1 to measurement at 6 months.
Secondary	Grip strength	The grip strength will be measured using the appropriate dynamometer. Strength will be measured 3 times for both hands and the highest value will be kept for further analysis.	Change from Baseline Grip Strength to measurement at 6 months.
Secondary	Knee extension	The knee extension measurement will be performed using isokinetic dynamometer.	Change from Baseline knee extension to measurement at 6 months.
Secondary	Patient Reported Outcome : SF-36	Electronically self administrated Patient Reported Outcome SF-36 will be assessed a SF-36 questionnaire.	Change from Baseline Patient Reported Outcome to measurement at 6 months.
Secondary	Patient Reported Outcomes : SarQoL	Electronically self administrated Patient Reported Outcome SarQoL will be assessed through the SarQoL questionnaire.	Change from Baseline Patient Reported Outcome to measurement at 6 months.
Secondary	Patient Reported Outcomes TSC-OD for patients with BMI>30	Electronically self administrated Patient Reported Outcomes will be assessed through the TSD-OC questionnaire for volunteers having BMI>30	Change from Baseline Patient Reported Outcome to measurement at 6 months.
Secondary	Patient Reported Outcomes (PAT-D)	Electronically administrated Patient Reported Outcome will be assessed with assistance of the investigator through the PAT-D questionnaire.	Change from Baseline Patient Reported Outcome to measurement at 6 months.
Secondary	Biomarkers	Biomarkers specific to Sarcopenia and to the Renin Angiotensin System ( Aldosterone; Renin; Myostatin; PIIINP; IL-6; hsCRP etc....) will be measured at baseline and at 6 months.	Change from Baseline Biomarkers to measurement at 6 months